Biocon Limited

rs,

12, 2025 To The Manager, BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code - 532523 Dear Sir/ Madam, Subject: Corporate Presenta

58%

boundaries to deliver impactful innovations Market cap of USD 2.9 bn5 Market cap of USD 707 mn6 58% of FY25 total revenue1 19% of FY25 total revenue1 23% of FY25 total revenue1 Listed at USD 1.3 b

19%

tful innovations Market cap of USD 2.9 bn5 Market cap of USD 707 mn6 58% of FY25 total revenue1 19% of FY25 total revenue1 23% of FY25 total revenue1 Listed at USD 1.3 bn on NASDAQ7 Creating stre

23%

of USD 2.9 bn5 Market cap of USD 707 mn6 58% of FY25 total revenue1 19% of FY25 total revenue1 23% of FY25 total revenue1 Listed at USD 1.3 bn on NASDAQ7 Creating strength through diversification

INR 84.5

of 31 March 2024| 2. For Biocon, as of 09 May 2025, sourced from BSE converted an exchange rate of INR 84.5/USD | 3. Data based on GMP certifications between Jan 2018 - Feb 2025 | 4. Frost & Sullivan (F&S):

52.7%

e, as of 09 May 2025, sourced from BSE converted an exchange rate of INR 84.5/USD. Biocon Ltd has a 52.7% stake in Syngene | 6. For Bicara, Market Cap as of 09 May 2025, from NASDAQ. Biocon Ltd has a 10.1

10.1%

2.7% stake in Syngene | 6. For Bicara, Market Cap as of 09 May 2025, from NASDAQ. Biocon Ltd has a 10.1% stake in Bicara Therapeutics | 7. Market cap of Bicara post listing as of 13 Sep 2024 4 Biocon’s

900 MT

• Serving global demand for statins & immunosuppressant APIs • API manufacturing capacity of 900 MTPA • ‘One-stop-shop’ for discovery, development and manufacturing • Opened new facility in Ba

3x

unches PRODUCT PORTFOLIO • Unique combination of Insulins and mABs • Global biosimilars to grow 3x to ~USD 67 bn in 20295 INDUSTRY TAILWIND • LoE of atleast 40+ blockbuster3 biologics between

4x

t Growing global pharmaceutical market with biologics representing an increasing share and growing ~4x of small molecules Global Pharmaceutical Market Size1 (USD bn) Top global therapeutic areas (TAs)

11%

Size1 (USD bn) Top global therapeutic areas (TAs) by projected global spending • Biologics CAGR = 11%, • Small molecule drugs CAGR = 3% 910 68% 32% 2019 1,184 59% 41% 2024 Meaningful increa

3%

c areas (TAs) by projected global spending • Biologics CAGR = 11%, • Small molecule drugs CAGR = 3% 910 68% 32% 2019 1,184 59% 41% 2024 Meaningful increase in mix of Biologics segment B

“Got approved in selected European countries 31 Robust portfolio across multiple therapeutic areas driving significant commercial success Syngene – Snapshot of Key Metrics USD 431 mn FY25 Revenue from operations 400+ active clients USD 56 mn1 FY25 PAT 8,235 headcount including 5,600+ talented scientists 14 out of top 20 pharma companies are clients2 400+ Patents held with clients 92% energy from renewable sources Infrastructure ~2.5 Mn sq.”

Markets

1

Markets

ex-US UK, EU2 MoW1 Therapeutic Area Molecule Therapeutic Area Molecule Therapeutic Area Molecule US Apixaban Atorvastatin Dabigatran Fluvastatin Ivabradine Cardiovascular Pravastatin Rivaroxaban Rosuvastatin Simvastatin Lovastatin Sacubitril Liraglutide Semaglutide Dapagliflozin Empagliflozin Linagliptin Repaglinide Sitagliptin Vildagliptin Anti-Diabetics Immunosuppressants Tacrolimus Mycophenolate Mofetil Mycophenolate Sodium Everolimus Sirolimus Pimecrolimus Dasatinib Everolimus Oncology Lenalidomide Anti-fungal Olaparib Cabozantinib Micafungin Anidulafungin Posaconazole Fingolimod Multiple Sclerosis Glatiramer Acetate Others Teriflunomide Orlistat Ticagrelor Deferasirox Brinzolamide Ivacaftor Mirabegron Nintedanib Lurasidone Cardiovascular Oncology Immunosuppressants Multiple Sclerosis Others Rosuvastatin Calcium Simvastatin Atorvastatin Pravastatin Labetalol HCI Dabigatran Sacubitril+valsartan Prazosin Rivaroxaban Everolimus (Afinitor) Everolimus (Zortress) Pemetrexed Lenalidomide